Biocon Business Ethics
-
Upload
nirjon-dip -
Category
Documents
-
view
242 -
download
0
Transcript of Biocon Business Ethics
-
8/10/2019 Biocon Business Ethics
1/21
Case Study: BioconIndias
Own Home-Grown Biotech
Company
-
8/10/2019 Biocon Business Ethics
2/21
Overview of Biocon
Biocon, Indias own home- grownbiotechnology company, wasestablished in 1978 as India's leadingbiotechnology company. It has evolved
over the past 30 years from an enzymemanufacturing unit to a fully integratedbiopharmaceutical enterprise, focusingon health care.
It has two subsidiary companies: Syngene International Limited Clinigene International Limited
-
8/10/2019 Biocon Business Ethics
3/21
BioconsPerformance
December, 2006- 44% increase in netprofit at Rs. 475.1m for third quarterwhere in previous year it was 327.9 m.
It earned a revenue Rs. 8630m, profitof Rs. 1080m 2006-2007 and grew 23%in first quarter of 2007-2008.
BSE - closing at Rs. 410.25
NSE - closing at Rs. 410.75 It gained Rs. 75 touching an intra-day
high of Rs. 445.65 on BSE.
-
8/10/2019 Biocon Business Ethics
4/21
Biocon in news Recently
Kiran Mazumder Shaw, the ChairpersonNew York Times: Indiasmother of invention
The Economist:IndiasBiotech Queen
Marketing license for BIOMab EGFR for
Pakistan on 18 January 2007Sign MoU with Neopharma for a joint venture
on 5 January 2007
Comprehensive portfolio of renal therapy
products on 8 March 2007Research partnership with Bristol-Myers
Squibb on 14 March 2007
-
8/10/2019 Biocon Business Ethics
5/21
Biocon - Important Milestones
Establishment of Biocon India1978
Manufacture and export enzymes to theUSA and Europe1979
US funding for proprietary technologies1989
Set up in-house research program1990
Establishment of Syngene1994
-
8/10/2019 Biocon Business Ethics
6/21
Biocon - Important Milestones
Enter to biopharmaceuticals and statins,leverage its technology platform1996
Become an independent entity1998
Set up Clinigene2000
Approval of manufacturing lovastatin by US
Food and Drug Administration2001 Clinigeneslaboratory receives CAP
accreditation2002
-
8/10/2019 Biocon Business Ethics
7/21
Biocon - Important Milestones
Develop human insulin on a Pichia expression system2003
New research centre in Bangalore
Partnership with Vaccinex, Inc to discover 4 therapeutic antibody2004
Sign commercial agreement to deliver insulin API in Asia, Africaand the Middle East2005
Launch Indias first cancer drug BIOMAb EGFR2006
Agreement with Abraxis Bioscience of US to sell its Abraxeme2007
-
8/10/2019 Biocon Business Ethics
8/21
Biocon and its Subsidiaries
Syngene
99.99% ownedsubsidiary
Paid-up capitalRs 28.75million on 18November1993
Clinigene
100% ownedsubsidiary
Incorporated onAugust 4, 2000with anauthorizedcapital of Rs 5
million
Paid-up capitalRs 500,000
BBPL
Collaborationwith CIMAB
SA, Cuba
51% equityparticipation byBiocon
Paid-up capitalRs 8.8 million
-
8/10/2019 Biocon Business Ethics
9/21
Biocon Product and Services
Biopharmaceuticals Biocon manufacturers a wide spectrum of
Biopharmaceuticals ranging from small
molecules to biological and dosage formswhich include antidiabetic agent , anti
hypertensive and antiinflammatory
agent , anti- oxidants ,haemostatic agents,
cholesterol-lowering agents, digestive-aidenzymes, hepatoprotective and
orthopedic agents.
-
8/10/2019 Biocon Business Ethics
10/21
Enzymes Biocon manufacturers and marketers a board
range of industrial Enzymes, food additivesand process aids which include amylases,
cellolases, lipases and proteases.
Food additives
Food additives manufactured and
marketed by Biocon include hydrocolloids,natural colors, specialty fats andspecialized proteins.
-
8/10/2019 Biocon Business Ethics
11/21
Services
Custom Research
Biocon subsidiary, Syngene, leverages its synthetics
chemistry skills to carry out custom research in early
stage drug discovery and development.
Clinical Research
Clinigene is a clinical research organization that
offers global biotechnology and pharmaceutical major
strong clinical trial services, regulatory and laboratory
capabilities for clinical drug development.
The value added services include patient registries
and clinical database in diabetes, lipidemia, oncology,
and cardiovascular diseases.
-
8/10/2019 Biocon Business Ethics
12/21
Biocons Corporate Social Responsibilities
Biocons CSR activities center has beenestablished with the aim of identifying andimplementing projects that impact the socialand economic scenario in the country.
Its main focus areas are to provide qualityhealth care and health education for thebetterment of Indian society.
Through its initiatives, Biocon Foundation by
establishing Arogya Raksha Yojana, aims toprovide high quality drugs at affordable pricesto the masses at all BioCare Pharmacies andparticipating clinics.
-
8/10/2019 Biocon Business Ethics
13/21
Clinical Trail And Drug Testing In India
A drug requires various testing beforetesting- Clinical Testing
India as preferred destination
- Clinical Trails
- Billion dollar business
Poor people of India
- Small compensation
-
8/10/2019 Biocon Business Ethics
14/21
The Indian Advantage
Cost saving offering of India
Huge number of patients
Poor monitoring mechanism
-
8/10/2019 Biocon Business Ethics
15/21
-
8/10/2019 Biocon Business Ethics
16/21
Unethical Practices of Biocon
Illegal clinical trials by Biocon In 2004, Biocon & Shantha Biotech in
Hyderabad came under security forconducting illegal clinical trials that led toeight deaths.
Biocon tested a genetically modified form ofinsulin without the proper approval from theDrug Controller General of India (DCGI).After the outcry against Shantha & Biocon,The Indian Govt. adopted stricter ethicalguidelines for clinical research, but onecannot be too sure that companies areabiding by the new rules.
-
8/10/2019 Biocon Business Ethics
17/21
Biocon Enhances Trade Operations inBangladesh
Biocon is on aggressive drive in Bangladesh
because of the countrys increasing
dependence on the lifestyle disorder drugs.
It is easier for companies like Biocon to put
up a plant in countries like Bangladesh since
the pollution norms are not strictly followed
there. Furthermore, clinical trials could be
easily conducted without any objection from
the government.
-
8/10/2019 Biocon Business Ethics
18/21
Environmental Infractions Company decides to set up a Rs. 10000
million manufacturing facility at Jawahar
Pharma City, SEZ, near Vishakhapatnam,
Andhrapradesh.
Andhrapradesh has been keen to get
Kiran Mazumdar Shaw to invest in the
state ever since it realized that Biotechmajor is unhappy over Bangalores
infrastructure.
-
8/10/2019 Biocon Business Ethics
19/21
Procedural lapses at Biocon Issue is lapses in making the drug
methylcobalamin , a form of vitamin
B12, & it was followed a seven stepsprocedure. However the company
skipped some steps & changed the
process by using an intermediate drug
imported without license. The state drug control authorities
cancelled the license.
-
8/10/2019 Biocon Business Ethics
20/21
Conclusion
The above news indicates that the
company is not keen on the
procedures and is willing to correct
only when identified and informed.
This also indicates that Bioconsshift
from Bangalore to Andhra Pradesh is
not only for the effluent treatmentfacility, but for other reasons as well.
-
8/10/2019 Biocon Business Ethics
21/21
Thank You